Lactulose Saar

Lactulose, the active ingredient in Lactulose Saar, is an osmotic laxative presented as an oral solution for oral use. It relieves constipation and reduces systemic ammonia levels, making it useful in the management of hepatic encephalopathy, primarily in adult patients. The product is approved for use in the European Union and is administered orally.

GNH USA supplies Lactulose Saar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution.

Lactulose is an osmotic laxative used to manage conditions affecting intestinal transit and ammonia metabolism.

- Constipation: softens stool and promotes bowel movements, relieving functional constipation. - Hepatic encephalopathy: lowers colonic ammonia production, helping to improve mental status in patients with liver disease. - Prevention of recurrent hepatic encephalopathy: maintains low ammonia levels to reduce the risk of symptom recurrence.

Lactulose is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Abdominal cramping - Flatulence - Diarrhea - Nausea - Bloating - Increased thirst

Serious or Rare Side Effects: - Severe electrolyte imbalance (e.g., hypokalemia) - Marked dehydration - Allergic reaction (rash, itching, swelling) - Acute hepatic decompensation in vulnerable patients

When prescribing lactulose, several safety considerations should be observed.

- Dose titration: adjust the dose to achieve 2–3 soft stools per day. - Fluid intake: ensure adequate hydration to prevent dehydration. - Renal impairment: monitor electrolytes and renal function regularly. - Diabetes: observe blood glucose, as lactulose may affect glycaemic control. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Lactulose may interact with other medicines, requiring attention to avoid reduced efficacy or increased risk.

Major Interactions (Avoid): - Broad‑spectrum antibiotics (e.g., rifaximin): may alter gut flora and diminish lactulose’s ammonia‑trapping effect. - Oral phosphate binders: can bind lactulose, reducing its availability.

Moderate Interactions (Monitor Closely): - Diuretics: increase the risk of electrolyte disturbances when combined with lactulose‑induced fluid shifts. - Insulin or oral hypoglycemics: lactulose can affect glucose metabolism, requiring closer glycaemic monitoring. - Probiotics: may modify bacterial fermentation patterns, influencing gas production and tolerability.